Immunotherapy and Radiation Therapy in cSCC and BCC

EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)

EP: 2.Immunotherapy Landscape in cSCC and BCC

Now Viewing

EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC

EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC

EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers

EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management

EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations

EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC

EP: 9.Staging Disease and Risk Stratification in CSCC and BCC

EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC

EP: 11.Socioeconomic Implications of CSCC and BCC

EP: 12.Immunosuppression in CSCC and BCC Treatment

EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers

EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care

This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.

Barker explained that immunotherapy is currently FDA-approved and standard of care for advanced cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) when surgery or radiation are no longer options. He stated radiation is sometimes used to palliate symptoms in immunotherapy nonresponders. Regarding integration with curative-intent radiation, he noted that in cSCC, immunotherapy is being studied adjuvant to surgery and radiation, not concurrently, based on success in this sequencing for non–small cell lung and gastroesophageal cancers. He contrasted this with failed trials combining immunotherapy and definitive chemoradiation for head and neck squamous cell carcinoma and other diseases. However, Barker suggested neoadjuvant immunotherapy prior to intense, definitive radiation could be explored in unresectable cSCC. Luke questioned whether smaller radiotherapy fields in skin cancer may better enable combinations with immunotherapy. Barker agreed that in advanced cSCC with both palliative and systemic therapy indications, concurrent radiation and immunotherapy out of clinical necessity may be reasonable.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.